Last reviewed · How we verify
ONM-100
At a glance
| Generic name | ONM-100 |
|---|---|
| Sponsor | OncoNano Medicine, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies (PHASE2)
- A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets (PHASE2)
- A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONM-100 CI brief — competitive landscape report
- ONM-100 updates RSS · CI watch RSS
- OncoNano Medicine, Inc. portfolio CI